EP14.05-022 The Drug Induced Interstitial Lung Disease in Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer

Abstract

Interstitial lung abnormalities (ILA) is defined as the changes affecting more than 5% of any lung zone, which included ground-glass or reticular abnormalities, diffuse centrilobular nodularity, nonemphysematous cysts, honeycombing, and traction bronchiectasis. ILA has been reported to be a risk factor for the development of drug-induced interstitial lung disease (D-ILD) by immune checkpoint inhibitors (ICI) monotherapy in non-small cell lung cancer. Combination of chemotherapy and immunotherapy (Chemo-ICI) has become the new standard of treatment for extensive-stage small cell lung cancer (ES-SCLC).